Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$251.41+0.62 (+0.25%)
Close on Nov 18, 2026Market cap $37.16BP/E 107.4Yield –
Biogen operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Biogen's operating cash flow for the twelve months ending Sep 30, 2026 was $2.25B, down 8.4% year over year. For fiscal 2025 it was $2.20B, down 23.3% from the year before. Over ten years it grew -5.6% a year on average. The highest annual figure on record is $7.08B in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.20B | -23.3% |
| FY2024 | Dec 31, 2024 | $2.88B | +85.9% |
| FY2023 | Dec 31, 2023 | $1.55B | +11.8% |
| FY2022 | Dec 31, 2022 | $1.38B | -62.0% |
| FY2021 | Dec 31, 2021 | $3.64B | -13.9% |
| FY2020 | Dec 31, 2020 | $4.23B | -40.2% |
| FY2019 | Dec 31, 2019 | $7.08B | +14.4% |
| FY2018 | Dec 31, 2018 | $6.19B | +36.0% |
| FY2017 | Dec 31, 2017 | $4.55B | -0.8% |
| FY2016 | Dec 31, 2016 | $4.59B | +17.0% |
| FY2015 | Dec 31, 2015 | $3.92B | +33.2% |
| FY2014 | Dec 31, 2014 | $2.94B | +25.5% |
| FY2013 | Dec 31, 2013 | $2.35B | +24.7% |
| FY2012 | Dec 31, 2012 | $1.88B | +8.8% |
| FY2011 | Dec 31, 2011 | $1.73B | +6.3% |
| FY2010 | Dec 31, 2010 | $1.62B | +51.1% |
| FY2009 | Dec 31, 2009 | $1.07B | -31.2% |
| FY2008 | Dec 31, 2008 | $1.56B | +53.4% |
| FY2007 | Dec 31, 2007 | $1.02B | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $640.80M | -49.6% |
| Q2 FY2026 | Jun 30, 2026 | $448.90M | +179.0% |
| Q1 FY2026 | Mar 31, 2026 | $645.50M | +148.9% |
| Q4 FY2025 | Dec 31, 2025 | $511.90M | -32.7% |
| Q3 FY2025 | Sep 30, 2025 | $1.27B | +36.0% |
| Q2 FY2025 | Jun 30, 2025 | $160.90M | -74.3% |
| Q1 FY2025 | Mar 31, 2025 | $259.30M | -53.1% |
| Q4 FY2024 | Dec 31, 2024 | $760.90M | +5987.2% |
| Q3 FY2024 | Sep 30, 2024 | $935.60M | +57.9% |
| Q2 FY2024 | Jun 30, 2024 | $625.80M | +28.5% |
| Q1 FY2024 | Mar 31, 2024 | $553.20M | +21.5% |
| Q4 FY2023 | Dec 31, 2023 | $12.50M | – |
| Q3 FY2023 | Sep 30, 2023 | $592.40M | -10.4% |
| Q2 FY2023 | Jun 30, 2023 | $487.00M | -33.9% |
| Q1 FY2023 | Mar 31, 2023 | $455.30M | +181.4% |
| Q4 FY2022 | Dec 31, 2022 | -$175.00M | -120.9% |
| Q3 FY2022 | Sep 30, 2022 | $661.00M | -17.9% |
| Q2 FY2022 | Jun 30, 2022 | $736.50M | -40.0% |
| Q1 FY2022 | Mar 31, 2022 | $161.80M | -79.0% |
| Q4 FY2021 | Dec 31, 2021 | $838.30M | – |
| Q3 FY2021 | Sep 30, 2021 | $805.30M | -31.8% |
| Q2 FY2021 | Jun 30, 2021 | $1.23B | -37.0% |
| Q1 FY2021 | Mar 31, 2021 | $769.00M | -47.6% |
| Q4 FY2020 | Dec 31, 2020 | -$367.10M | -118.7% |
| Q3 FY2020 | Sep 30, 2020 | $1.18B | -30.3% |
| Q2 FY2020 | Jun 30, 2020 | $1.95B | -0.8% |
| Q1 FY2020 | Mar 31, 2020 | $1.47B | +0.5% |
| Q4 FY2019 | Dec 31, 2019 | $1.96B | +3.4% |
| Q3 FY2019 | Sep 30, 2019 | $1.69B | -2.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.96B | +78.7% |
| Q1 FY2019 | Mar 31, 2019 | $1.46B | +0.2% |
| Q4 FY2018 | Dec 31, 2018 | $1.90B | +24.8% |
| Q3 FY2018 | Sep 30, 2018 | $1.74B | +6.6% |
| Q2 FY2018 | Jun 30, 2018 | $1.10B | -6.0% |
| Q1 FY2018 | Mar 31, 2018 | $1.46B | +519.5% |
| Q4 FY2017 | Dec 31, 2017 | $1.52B | -4.0% |
| Q3 FY2017 | Sep 30, 2017 | $1.63B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.17B | – |
| Q1 FY2017 | Mar 31, 2017 | $235.20M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.58B | – |
See a number that looks wrong?